A Review on Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of Pancreatic Lesions
Fred G. Karaisz,
Osama O. Elkelany,
Benjamin Davies,
Gerard Lozanski,
Somashekar G. Krishna
Affiliations
Fred G. Karaisz
Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Osama O. Elkelany
Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Benjamin Davies
College of Medicine, The Ohio State University, Columbus, OH 43210, USA
Gerard Lozanski
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus OH 43210, USA
Somashekar G. Krishna
Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
The morbidity associated with pancreatectomies limits surgical options for high-risk patients with pancreatic neoplasms that warrant resection. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) offers a minimally invasive and potentially definitive means to treat pancreatic neuroendocrine tumors and precancerous pancreatic cystic lesions. In addition, EUS-RFA may play a role in the treatment and palliation of non-surgical cases of pancreatic adenocarcinoma. The efficacy of RFA appears to be further enhanced by systemic immunomodulatory effects. Here, we review current studies on the developing role of EUS-RFA in these pancreatic pathologies.
